DOTFE
Pharmaceutical compound
From Wikipedia, the free encyclopedia
DOTFE, also known as 4-(2,2,2-trifluoroethyl)-2,5-dimethoxyamphetamine, is a drug of the phenethylamine, amphetamine, and DOx families.[1][2][3] It is a close analogue of known psychedelics like the DOx psychedelic DOTFM and the 2C psychedelics 2C-TFE and 2C-TFM.[1][3][2] The drug was predicted to bind to the serotonin 5-HT2A receptor, with a predicted affinity (Ki) of 50 nM.[2] It was inactive in humans at doses of up to 3 mg, but higher doses were not assessed.[1][3] DOTFE is expected to be a potent psychedelic at active doses.[1] It was first described in the scientific literature by at least 1999.[2] DOTFE was evaluated in humans by Daniel Trachsel, with these reports published in 2012 and 2013.[3][1]
- None
| |
| Clinical data | |
|---|---|
| Other names | 4-(2,2,2-Trifluoroethyl)-2,5-dimethoxyamphetamine; 2,5-Dimethoxy-4-(2,2,2-trifluoroethyl)amphetamine |
| ATC code |
|
| Identifiers | |
| |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C13H18F3NO2 |
| Molar mass | 277.287 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
